AOTMiT: Transparency Council on asthma and infertility treatment, among others

The agenda includes:

1 Prepare an opinion on Corifollitropinum alfa, ganirelixum, cetrorelixum, triptorelinum, folitropinum delta, follitropinum alfa, follitropinum beta, urofollitropinum, menotropinum for the indication: use in hormonal therapy for the treatment of infertility, in patients eligible for the Health Policy Program: "Infertility treatment involving medically assisted procreation procedures, including in vitro fertilization conducted in a medically assisted procreation center, for 2024-2028".

2 Prepare a position paper on the evaluation of the medicinal product Tezspire (tezepelumabum) within the framework of the drug program B.44. "Treatment of patients with severe asthma (ICD-10: J45, J82)".

3 Prepare an opinion on the continuation of reimbursement in off-label indications for the active substances: risperidone, aripiprazole, topiramate, sulpiride, zyprasidone indication: Tourette syndrome.

Source: AOTMIT